RHJA
IRD

Rice Hall James & Associates’s Opus Genetics IRD Stock Holding History

Rice Hall James & Associates’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-223,589
Closed -$342K – 269
2024
Q2 		$342K Sell
223,589
-68,396
-23% -$118K 0.02% 247
2024
Q1 		$587K Sell
291,985
-279,792
-49% -$710K 0.03% 226
2023
Q4 		$1.72M Sell
571,777
-256,851
-31% -$759K 0.1% 183
2023
Q3 		$2.78M Sell
828,628
-20,658
-2% -$83K 0.18% 132
2023
Q2 		$3.69M Buy
849,286
+40,169
+5% +$191K 0.21% 113
2023
Q1 		$3.03M Buy
809,117
+3,050
+0.4% +$11K 0.17% 141
2022
Q4 		$2.85M Buy
806,067
+265,719
+49% +$699K 0.16% 144
2022
Q3 		$1.09M Buy
540,348
+212,854
+65% +$459K 0.06% 230
2022
Q2 		$629K Buy
327,494
+182,468
+126% +$415K 0.03% 240
2022
Q1 		$470K Buy
145,026
+12,593
+10% +$43.1K 0.02% 254
2021
Q4 		$494K Buy
+132,433
New +$531K 0.02% 262

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rice Hall James & Associates's IRD Position: Q3 2024 in Review

Rice Hall James & Associates sold out of Opus Genetics (IRD) in Q3 2024, closing a stake of 223,589 shares — an estimated $342K sold.

Rice Hall James & Associates first reported a position in IRD in Q4 2021 and held it in 11 quarters. The position peaked at $3.69M in Q2 2023. 38 funds tracked by Wall St. Rank hold IRD as of Q3 2024.

  • Rice Hall James & Associates reported no remaining Opus Genetics position as of Q3 2024 after selling out during the quarter.
  • Rice Hall James & Associates sold 223,589 Opus Genetics shares in Q3 2024, an estimated $342K.
  • Rice Hall James & Associates first reported a position in Opus Genetics in Q4 2021 and held it in 11 quarters.
  • Rice Hall James & Associates's Opus Genetics position peaked at $3.69M in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2024.

Based on Rice Hall James & Associates's 13F filing for Q3 2024, filed 28 Oct 2024.